Cargando…

Post-genomic platform for development of oligonucleotide vaccines against RNA viruses: diamond cuts diamond

The coronavirus pandemic has starkly demonstrated the need to create highly effective vaccines against various viral diseases. The emerging new platforms for vaccine creation (adenovirus vectors and mRNA vaccines) have shown their worth in the fight against the prevention of coronavirus infection. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Oberemok, V. V., Andreeva, O. A., Laikova, K. V., Novikov, I. A., Kubyshkin, A. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075145/
https://www.ncbi.nlm.nih.gov/pubmed/35523969
http://dx.doi.org/10.1007/s00011-022-01582-2
_version_ 1784701616573644800
author Oberemok, V. V.
Andreeva, O. A.
Laikova, K. V.
Novikov, I. A.
Kubyshkin, A. V.
author_facet Oberemok, V. V.
Andreeva, O. A.
Laikova, K. V.
Novikov, I. A.
Kubyshkin, A. V.
author_sort Oberemok, V. V.
collection PubMed
description The coronavirus pandemic has starkly demonstrated the need to create highly effective vaccines against various viral diseases. The emerging new platforms for vaccine creation (adenovirus vectors and mRNA vaccines) have shown their worth in the fight against the prevention of coronavirus infection. However, adenovirus vectors and mRNA vaccines have a serious disadvantage: as a rule, only the S protein of the coronavirus is presented as an antigen. This tactic for preventing infection allows the ever-mutating virus to escape quickly from the immunity protection provided by such vaccines. Today, viral genomic databases are well-developed, which makes it possible to create new vaccines on a fundamentally new post-genomic platform. In addition, the technology for the synthesis of nucleic acids is currently experiencing an upsurge in demand in various fields of molecular biology. The accumulated experience suggests that the unique genomic sequences of viruses can act as antigens that trigger powerful humoral and cellular immunity. To achieve this effect, the following conditions must be created: the structure of the nucleic acid must be single-stranded, have a permanent 3D nanostructure, and have a unique sequence absent in the vaccinated organism. Oligonucleotide vaccines are able to resist the rapidly changing genomic sequences of RNA viruses by using conserved regions of their genomes to generate a long-term immune response, acting according to the adage that a diamond cuts a diamond. In addition, oligonucleotide vaccines will not contribute to antibody-dependent enhanced infection, since the nucleic acid of the coronavirus is inside the viral particle. It is obvious that new epidemics and pandemics caused by RNA viruses will continue to arise periodically in the human population. The creation of new, safe, and effective platforms for the production of vaccines that can flexibly change and adapt to new subtypes of viruses is very urgent and at this moment should be considered as a strategically necessary task.
format Online
Article
Text
id pubmed-9075145
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-90751452022-05-06 Post-genomic platform for development of oligonucleotide vaccines against RNA viruses: diamond cuts diamond Oberemok, V. V. Andreeva, O. A. Laikova, K. V. Novikov, I. A. Kubyshkin, A. V. Inflamm Res Comment The coronavirus pandemic has starkly demonstrated the need to create highly effective vaccines against various viral diseases. The emerging new platforms for vaccine creation (adenovirus vectors and mRNA vaccines) have shown their worth in the fight against the prevention of coronavirus infection. However, adenovirus vectors and mRNA vaccines have a serious disadvantage: as a rule, only the S protein of the coronavirus is presented as an antigen. This tactic for preventing infection allows the ever-mutating virus to escape quickly from the immunity protection provided by such vaccines. Today, viral genomic databases are well-developed, which makes it possible to create new vaccines on a fundamentally new post-genomic platform. In addition, the technology for the synthesis of nucleic acids is currently experiencing an upsurge in demand in various fields of molecular biology. The accumulated experience suggests that the unique genomic sequences of viruses can act as antigens that trigger powerful humoral and cellular immunity. To achieve this effect, the following conditions must be created: the structure of the nucleic acid must be single-stranded, have a permanent 3D nanostructure, and have a unique sequence absent in the vaccinated organism. Oligonucleotide vaccines are able to resist the rapidly changing genomic sequences of RNA viruses by using conserved regions of their genomes to generate a long-term immune response, acting according to the adage that a diamond cuts a diamond. In addition, oligonucleotide vaccines will not contribute to antibody-dependent enhanced infection, since the nucleic acid of the coronavirus is inside the viral particle. It is obvious that new epidemics and pandemics caused by RNA viruses will continue to arise periodically in the human population. The creation of new, safe, and effective platforms for the production of vaccines that can flexibly change and adapt to new subtypes of viruses is very urgent and at this moment should be considered as a strategically necessary task. Springer International Publishing 2022-05-06 2022 /pmc/articles/PMC9075145/ /pubmed/35523969 http://dx.doi.org/10.1007/s00011-022-01582-2 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Comment
Oberemok, V. V.
Andreeva, O. A.
Laikova, K. V.
Novikov, I. A.
Kubyshkin, A. V.
Post-genomic platform for development of oligonucleotide vaccines against RNA viruses: diamond cuts diamond
title Post-genomic platform for development of oligonucleotide vaccines against RNA viruses: diamond cuts diamond
title_full Post-genomic platform for development of oligonucleotide vaccines against RNA viruses: diamond cuts diamond
title_fullStr Post-genomic platform for development of oligonucleotide vaccines against RNA viruses: diamond cuts diamond
title_full_unstemmed Post-genomic platform for development of oligonucleotide vaccines against RNA viruses: diamond cuts diamond
title_short Post-genomic platform for development of oligonucleotide vaccines against RNA viruses: diamond cuts diamond
title_sort post-genomic platform for development of oligonucleotide vaccines against rna viruses: diamond cuts diamond
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075145/
https://www.ncbi.nlm.nih.gov/pubmed/35523969
http://dx.doi.org/10.1007/s00011-022-01582-2
work_keys_str_mv AT oberemokvv postgenomicplatformfordevelopmentofoligonucleotidevaccinesagainstrnavirusesdiamondcutsdiamond
AT andreevaoa postgenomicplatformfordevelopmentofoligonucleotidevaccinesagainstrnavirusesdiamondcutsdiamond
AT laikovakv postgenomicplatformfordevelopmentofoligonucleotidevaccinesagainstrnavirusesdiamondcutsdiamond
AT novikovia postgenomicplatformfordevelopmentofoligonucleotidevaccinesagainstrnavirusesdiamondcutsdiamond
AT kubyshkinav postgenomicplatformfordevelopmentofoligonucleotidevaccinesagainstrnavirusesdiamondcutsdiamond